AxoGen sees Q4 revenue $49.4M, consensus $47.44M

The company said, “Full-year 2024 revenue is expected to be approximately $187.3 million, which represents a 17.8% increase over the full-year of 2023.Our positive performance reflects continued improvements in the execution of our commercial strategies, including a focus on high-potential accounts in Extremities and OMF-Head & Neck applications, adoption of Axogen’s (AXGN) complete peripheral nerve surgical algorithm across all procedures, and continued adoption of Resensation as an expectation for post mastectomy breast reconstruction procedures. We expect full year gross margin to be above 75.5%. Total balance of cash, cash equivalents and investments on December 31, 2024, is expected to be approximately $39.5 million, representing an increase of approximately $2.5 million over that balance at the end of 2023.”